Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

FDA Panel To Mull Risks Of Amgen’s Enbrel For Pediatric Psoriasis

This article was originally published in The Pink Sheet Daily

Executive Summary

Agency’s Dermatologic and Ophthalmic Drugs Advisory Committee also will discuss whether the sponsor submitted sufficient information to extend approval to the pediatric population.

You may also be interested in...



FDA Committee Recommends Amgen’s Enbrel For Approval In Pediatric Psoriasis

Panel sees benefit of giving physicians freedom to choose the treatment and gaining further data through Amgen’s proposed safety registry and ongoing study.

FDA Committee Recommends Amgen’s Enbrel For Approval In Pediatric Psoriasis

Panel sees benefit of giving physicians freedom to choose the treatment and gaining further data through Amgen’s proposed safety registry and ongoing study.

Anti-TNFs’ Link To Cancer In Children Under Investigation By FDA

Agency is investigating approximately 30 reports of cancer in pediatric patients.

Related Content

Topics

Latest Headlines
See All
UsernamePublicRestriction

Register

PS067917

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel